<DOC>
	<DOCNO>NCT01376908</DOCNO>
	<brief_summary>This Phase 3b , multicenter , open-label , randomize , control study evaluate efficacy , safety population pharmacokinetics sapropterin dihydrochloride ( Kuvan® ) less 4 year-old infant child phenylketonuria ( PKU ) .</brief_summary>
	<brief_title>Kuvan® Phenylketonuria Patients Less Than 4 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Male female PKU infant young child less ( &lt; ) 4 year age schedule Day 1 visit 26week study period ( take consideration maximum 21 day screen period ) Confirmed clinical biochemical PKU , include least two previous blood Phe level great equal ( &gt; = ) 400 micromol per liter ( mcmol/L ) obtain 2 separate occasion Previously respond , assess Investigator , tetrahydrobiopterin ( BH4 ) test , 3 follow criterion satisfy : 1 . The BH4 dose 20 milligram per kilogram per day ( mg/kg/day ) 2 . The duration test least 24 hour 3 . A 30 % decrease blood Phe level . Defined level dietary Phe tolerance consistent diagnosis PKU Good adherence dietary treatment , include prescribed dietary Phe restriction prescribe amount Phefree protein supplement lowPhe food Maintenance blood Phe level within therapeutic target range 120360 mcmol/L ( define &gt; =120 &lt; 360 mcmol/L ) 4month period prior Screening , assess Investigator Parent ( ) and/or guardian ( ) willing comply study procedure , maintain strict adherence diet , willing able provide write , sign informed consent nature study explain prior study procedure Use Kuvan® , Biopten® , unregistered preparation tetrahydrobiopterin within previous 30 day , unless purpose BH4 responsiveness test Previous exposure Kuvan® , Biopten® , unregistered preparation tetrahydrobiopterin great ( &gt; ) 30 day Known hypersensitivity Kuvan® excipients Known hypersensitivity approve nonapproved formulation tetrahydrobiopterin Previous diagnosis BH4 deficiency Current use methotrexate , trimethoprim , dihydrofolate reductase inhibitor Current use medication know affect nitric oxide synthesis , metabolism action Current use levodopa Current use experimental/other investigational unregistered drug may affect study outcome Inability comply study procedure Inability tolerate oral intake History organ transplantation Concurrent disease condition would interfere study participation increase risk adverse event , include seizure disorder , corticosteroid administration , active malignancy , diabetes mellitus , severe congenital heart disease , renal hepatic failure Other significant disease Investigator 's opinion would exclude subject trial Any condition , view Principal Investigator render subject high risk failure comply treatment complete study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Phenylketonuria ( PKU )</keyword>
	<keyword>Kuvan® ( Sapropterin )</keyword>
	<keyword>Phe-restricted diet</keyword>
	<keyword>Paediatric &lt; 4 year old</keyword>
	<keyword>responder BH4</keyword>
	<keyword>Phe tolerance</keyword>
</DOC>